Covidien (Dublin, Ireland) will forego gathering additional clinical data for its Solitaire FR revascularization device and seek FDA approval. The move comes after the data safety monitoring board (DSMB) reviewed data from the SWIFT (Solitaire FR With Intention For Thrombectomy) trial and recommended that Covidien stop enrolling patients and submit the trial data to the FDA for approval. (Medical Device Daily) Read More
